Outlook Therapeutics, Inc. announced a private placement of 714,286 shares at a price of $7 per share for the gross proceeds of $5,000,002 and accompanying warrant to purchase one and a half shares of common stock on April 15, 2024. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029. The transaction included participation from returning investor,
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.9 USD | +4.91% | +1.54% | +0.25% |
May. 21 | CoStar Group has room for expansion | |
May. 16 | Transcript : Outlook Therapeutics, Inc., Q2 2024 Earnings Call, May 16, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.25% | 185M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC